<SEC-DOCUMENT>0000914475-23-000043.txt : 20230503
<SEC-HEADER>0000914475-23-000043.hdr.sgml : 20230503
<ACCEPTANCE-DATETIME>20230503073226
ACCESSION NUMBER:		0000914475-23-000043
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230503
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230503
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		23881691

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20230503.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:04891992-6d88-4b4d-ad30-4ef395bc4d22,g:7f1b5e81-c09c-4145-9bdb-6e2811b106b6,d:5ab7a90e4681492cb45f6f4a5dc3acd7--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20230503</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN180L2ZyYWc6MTc3ZDM4MTNlYjdlNDZhYmFiMDg3NjkxZDlmNDVlOGEvdGFibGU6MGRlMDFkMDQ3OWU2NGY2NDhkZWUzYTZmZWYxZjk4YjAvdGFibGVyYW5nZTowZGUwMWQwNDc5ZTY0ZjY0OGRlZTNhNmZlZjFmOThiMF8wLTEtMS0xLTE3NDQ3MA_a9a292d4-598e-4ddc-a2da-588172012b05">false</ix:nonNumeric><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN180L2ZyYWc6MTc3ZDM4MTNlYjdlNDZhYmFiMDg3NjkxZDlmNDVlOGEvdGFibGU6MGRlMDFkMDQ3OWU2NGY2NDhkZWUzYTZmZWYxZjk4YjAvdGFibGVyYW5nZTowZGUwMWQwNDc5ZTY0ZjY0OGRlZTNhNmZlZjFmOThiMF8xLTEtMS0xLTE3NDQ3MA_188b887c-70b0-4193-89d7-f9790b502907">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20230503.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-03</xbrli:startDate><xbrli:endDate>2023-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ab7a90e4681492cb45f6f4a5dc3acd7_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAy_4245022a-a924-4e4c-912e-82bca186da13">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8yMjI_8a6da6db-7247-4498-97ea-bbbbb6b2de73">May&#160;3, 2023</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><img src="nbix-20230503_g1.jpg" alt="nbix.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAz_b3c7dc7a-4207-4a01-9599-a1ffa19a7454">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk3_59708936-7215-455b-affb-849dbd03afd5">Delaware</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(State or other jurisdiction<br/>of incorporation)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzky_0bc5aeb8-b38c-42e1-905d-6e7c6410334b">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(Commission<br/>File Number)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.574%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk4_4cf2bd07-078c-494d-b9ec-a4aceb9ba188">33-0525145</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(IRS Employer<br/>Identification No.)</span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk5_37710e17-c1aa-4ba0-8d2e-9fe168453bae">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAw_95fb4e93-13ae-49a1-bbaf-3f87550df4cf">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzkz_1204249c-6d6b-4ab7-83b8-f1256dab13d7">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV81MjQ_ec650a7f-7de1-4545-a09d-3eca7f297abe">92130</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV81Mzg_c8af3bb9-7cf2-4bb9-b447-1b47817bb83f">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzg3_bd2ef453-5fa5-4486-9349-21e8793eb130">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAx_fcd8a377-4df4-4898-b6d1-0815678d252a">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk0_0bc6c2d8-83bb-40a8-a17a-9cdb5a833a82">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk1_6ecbdc44-1591-4792-be79-11df10cb2c1e">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzg1_ea68de5f-02e7-4f0a-a53b-e8ffb6d60f8f">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTAtMS0xLTE3NDQ3MA_4bf3d6dd-e50f-43a6-b6e7-aecfc0e06de7">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTItMS0xLTE3NDQ3MA_0c4c5208-5d17-44ba-8fb6-df64960c56da">NBIX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTQtMS0xLTE3NDQ3MA_f5c363f3-bd2a-46b1-8318-62984a0d234b">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzkx_7146d33f-6471-487b-810a-6a2dad76d578">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ab7a90e4681492cb45f6f4a5dc3acd7_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;3, 2023, Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March&#160;31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q1-2023xearningsrelease.htm">Press Release dated May 3, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ab7a90e4681492cb45f6f4a5dc3acd7_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May&#160;3, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principle Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q1-2023xearningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5a988bcdfc0b447192c2218279238584_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Neurocrine Biosciences Reports First Quarter 2023 Financial Results </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) First Quarter Net Product Sales of $410 Million</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1.77 Billion</font></div><div style="margin-bottom:6pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAN DIEGO, May 3, 2023 - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today announced its financial results for the first quarter ended March&#160;31, 2023 and provided an update on its 2023 financial guidance.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;INGREZZA&#8217;s first quarter results highlight the steady progress we are making to help improve the lives of patients living with tardive dyskinesia, yet we still have a tremendous opportunity to help even more patients for many years to come,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;We are executing well across our clinical portfolio and anticipate several important milestones in the months ahead including the August 20th PDUFA date for valbenazine for the treatment of chorea associated with Huntington disease. In addition, we remain on-track for top-line data in the second half of this year for several investigational programs, including crinecerfont for the treatment of pediatric and adult congenital adrenal hyperplasia.&#8221;</font></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions, except per share data)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Product sales, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">305.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">420.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">310.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Research and Development (R&#38;D)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">89.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Selling, General and Administrative (SG&#38;A)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">216.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">176.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net (loss) income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP (loss) earnings per share &#8211; diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net (loss) income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(49.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP (loss) earnings per share &#8211; diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,139.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,288.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INGREZZA Net Product Sales Highlights&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">INGREZZA first quarter 2023 net product sales were $410 million and grew 36% compared vs. the first quarter 2022</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Record number of new patients received therapy during the first quarter of 2023</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter Financial Highlights&#58;</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">First quarter 2023 GAAP net loss and loss per share of $77 million and $0.79, respectively, compared with first quarter 2022 GAAP net income and earnings per share of $14 million and $0.14, respectively</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">First quarter 2023 non-GAAP net loss and loss per share of $50 million and $0.51, respectively, compared with first quarter 2022 non-GAAP net income and earnings per share of $30 million and $0.30, respectively</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Differences in first quarter 2023 GAAP and non-GAAP operating expenses compared with first quarter 2022 driven by&#58;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.75pt">Acquired In-Process R&#38;D (IPR&#38;D) expense of $144 million in first quarter 2023 associated with expansion of strategic partnership with Voyager Therapeutics, Inc. (Voyager)</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.75pt">Increased R&#38;D expense in support of an expanded and advancing clinical portfolio</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.75pt">Increased SG&#38;A expense primarily due to ongoing commercial initiatives, including the deployment of the expanded salesforce in April 2022</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">At March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of approximately $1.1&#160;billion</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A reconciliation of GAAP to non-GAAP financial results can be found in Table 3 and Table 4 at the end of this earnings release.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recent Events&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">On January 8, 2023, we entered into a new strategic collaboration with Voyager, which became effective on February 21, 2023, to acquire the worldwide rights to Voyager&#8217;s GBA1 gene therapy program for Parkinson&#8217;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets for up-front consideration of $175 million.</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the first quarter of 2023, we provided BIAL with written notice of termination of the license agreement to commercialize and market ONGENTYS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (opicapone), an approved adjunctive therapy for patients with Parkinson's disease, in the United States and Canada. We determined that continued commercialization of ONGENTYS is unsustainable. The termination is anticipated to be effective in December 2023. ONGENTYS is an important, safe and effective adjunctive treatment option for Parkinson&#8217;s disease patients. We intend to work with BIAL to ensure an orderly transition of the commercialization of ONGENTYS and to ensure patients have continued access to ONGENTYS.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reiterated 2023 INGREZZA Sales and Updated Operating Expense Guidance&#58;  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INGREZZA Net Product Sales </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,670&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,770&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP R&#38;D expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">550&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">580&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">495&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">525&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP and Non-GAAP IPR&#38;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">144&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">144&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP SG&#38;A expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">850&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">870&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">730&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">INGREZZA sales guidance for fiscal 2023 reflects expected sales of INGREZZA in tardive dyskinesia only. </font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">GAAP R&#38;D guidance reflects the progression of the Company&#8217;s pipeline including multiple compounds in mid- to late-phase clinical development, meaningful investments in the muscarinic portfolio and expanded pre-clinical research efforts. GAAP R&#38;D guidance includes amounts for milestones that are probable of achievement or have been achieved. </font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">IPR&#38;D guidance reflects acquired in-process research and development once significant collaboration and licensing arrangements have been completed. IPR&#38;D guidance includes $143.9 million associated with the new strategic collaboration with Voyager.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">GAAP SG&#38;A guidance reflects the continued investment in the expanded commercial organization to support INGREZZA and to support the anticipated approval for valbenazine to treat patients with chorea associated with Huntington disease. </font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $55 million in R&#38;D and $120 million in SG&#38;A.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2023 Expected Pipeline Milestones and Key Activities</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;2023 Milestones &#47; Key Activities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Valbenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective VMAT2 Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chorea in Huntington Disease</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PDUFA Aug. 20, 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Crinecerfont</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(CRF1 Receptor Antagonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Adult)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Registrational Data in Early Q4 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Pediatric)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Registrational Data in Early Q4 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-921352</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Selective Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6 Channel Blocker)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Focal Onset Seizure in Adults</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Phase 2 Data in Q4 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1065846</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(GPR-139 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anhedonia in Major Depressive Disorder</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Phase 2 Data in Q4 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1117570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8225;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Dual M1&#47; M4 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Treatment of Schizophrenia</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate Phase 1 Study</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Chemical Entity or Entities</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indication(s) TBD</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate at Least One Phase 1 Study</font></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key&#58; VMAT2 &#61; Vesicular Monoamine Transporter 2&#59; CFR1 &#61; Corticotropin-Releasing Factor Type 1&#59; Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.6 &#61; Sodium Channel, Voltage-Gated&#59; M1 &#47; M4 &#61; M1 &#47; M4 Muscarinic Receptor&#59; GPR &#61; Orphan G Protein Coupled Receptor</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurocrine Biosciences Partners&#58; * Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia&#59; ** In-Licensed from Xenon Pharmaceuticals&#59; &#8224; Partnered with Takeda Pharmaceutical Company Limited&#59; &#8225; In-Licensed from Sosei Group Corporation</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast Today at 8&#58;00 AM Eastern Time</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences will hold a live conference call and webcast today at 8&#58;00 a.m. Eastern Time (5&#58;00 a.m. Pacific Time). Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID&#58; NBIX. The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">About Neurocrine Biosciences</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit </font><font style="color:#00b050;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">neurocrine.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and follow the company on LinkedIn, Twitter and Facebook. (*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">in collaboration with AbbVie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following non-GAAP financial measures&#58; non-GAAP R&#38;D expense, non-GAAP SG&#38;A expense, and non-GAAP net income and net income per share. When preparing the non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these non-GAAP financial measures exclude&#58; non-cash stock-based compensation expense, loss on extinguishment of convertible senior notes, non-cash interest expense related to convertible debt, non-cash amortization expense related to acquired intangible assets, acquisition-related transaction costs, changes in fair value of equity security investments, changes in foreign currency exchange rates and certain adjustments to income tax expense. These non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these non-GAAP financial measures help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&#38;D and SG&#38;A expenses on both a GAAP and a non-GAAP basis. A reconciliation of these GAAP financial results to non-GAAP financial results is included in the attached financial information.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to&#58; the benefits to be derived from our products and product candidates&#59; the value our products and&#47;or our product candidates may bring to patients&#59; the continued success of INGREZZA&#59; our financial and operating performance, including our future revenues, expenses, or profits&#59; our collaborative partnerships&#59; expected future clinical and regulatory milestones&#59; and the timing of the initiation and&#47;or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58; our future financial and operating performance&#59; risks and uncertainties associated with the commercialization of INGREZZA&#59; risks related to the development of our product candidates&#59; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks associated with U.S. federal or state legislative or regulatory and&#47;or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue&#59; risks associated with potential generic entrants for our products&#59; and other risks described in our periodic reports filed with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Contact&#58; Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tony Jewell (Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7578<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;neurocrine.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Todd Tushla (Investors)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;neurocrine.com</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:76.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating (loss) income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.2)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity security investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income and other, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before (benefit from) provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and debt securities available-for-sale</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity security investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net (loss) income</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense - R&#38;D</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense - SG&#38;A</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest related to convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash amortization related to acquired intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of equity security investments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect related to reconciling items </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net (loss) income </font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.5)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Reflects periodic fluctuations in the fair values of the Company&#8217;s equity security investments.</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Estimated income tax effect of non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance and adjustments to exclude tax benefits or expenses associated with non-cash stock-based compensation.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP EXPENSES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:74.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP cost of revenues</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash amortization related to acquired intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP cost of revenues</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP SG&#38;A</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP other income, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest related to convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of equity security investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP other income (expense), net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20230503.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04891992-6d88-4b4d-ad30-4ef395bc4d22,g:7f1b5e81-c09c-4145-9bdb-6e2811b106b6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20230503" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20230503">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20230503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20230503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20230503_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04891992-6d88-4b4d-ad30-4ef395bc4d22,g:7f1b5e81-c09c-4145-9bdb-6e2811b106b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_dd4a12c5-8827-4ce4-8dda-377012eaccf2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9a2f3792-d053-42eb-8c1d-2fffa9c540bf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f6792f47-f26e-42ab-a6b6-a8a09395e437_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4aa23b7a-9272-4419-bc1e-ace87f56372c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_aac926b6-3e54-4d35-a2d7-b7d3835845f5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_196ea0ca-ebe0-4034-917e-92b8b4b863cf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6974c345-e3e6-4085-a3d6-fab74812d6da_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a217bb09-df0d-4dfc-9952-5b953bee25fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_81d47fdf-c5f1-4e51-80d5-bd83ecbba991_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0cc2a807-0edb-42ef-aec7-c25a6cad5571_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b8c742e9-1e1d-4a81-a516-3f87b714e196_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a2a3d6bf-bb8f-43a3-9313-3640ba1fe426_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b96a823a-7e17-486f-aea8-f4096447de86_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_076cd3d4-bbe2-406b-9ebc-4f0c3f54b254_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5656f546-d0b6-4ddc-9342-537c9107ee30_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5aa0fa2a-dfb7-4539-8fc1-275814083fce_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8d42af71-b5de-4ca4-bf91-1531a77312cf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fb2cadf9-71bc-4d5d-b258-5acf5200c090_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d21a1f7a-67cb-4585-a0e3-bbcc0084218d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_843eb5f2-8718-42ef-aced-b2b06a55731a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9d596c42-bb09-4cbb-98c0-e3f89afe299c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7334276d-b497-43f4-b3bc-7bec15d64a9e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20230503_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04891992-6d88-4b4d-ad30-4ef395bc4d22,g:7f1b5e81-c09c-4145-9bdb-6e2811b106b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20230503.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b1c49087-f138-4b62-a8d4-6ed97e1dbc0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_DocumentType_b1c49087-f138-4b62-a8d4-6ed97e1dbc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_371d18c9-d238-42c7-b665-da220e3be578" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_DocumentPeriodEndDate_371d18c9-d238-42c7-b665-da220e3be578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dad9efcb-f0ca-4a19-9fae-9cb96de324d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityRegistrantName_dad9efcb-f0ca-4a19-9fae-9cb96de324d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_039a7379-eeea-4ef3-9326-22c8eea09d82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_039a7379-eeea-4ef3-9326-22c8eea09d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_69f9f565-8f1c-4e99-879a-e5c918f2ec26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityFileNumber_69f9f565-8f1c-4e99-879a-e5c918f2ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b8d18bc2-bb36-4112-8f4d-0757ab7b69c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityTaxIdentificationNumber_b8d18bc2-bb36-4112-8f4d-0757ab7b69c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ed43758d-a096-4737-8815-39dde8ec6629" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityAddressAddressLine1_ed43758d-a096-4737-8815-39dde8ec6629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a7c2c5e6-562f-45e9-ad83-653495713bf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityAddressCityOrTown_a7c2c5e6-562f-45e9-ad83-653495713bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_56db6b96-7e45-49b4-b2b0-6a81724da536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityAddressStateOrProvince_56db6b96-7e45-49b4-b2b0-6a81724da536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_976c5b21-ebd3-405a-90d1-07b61f58f688" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityAddressPostalZipCode_976c5b21-ebd3-405a-90d1-07b61f58f688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dd6a1231-0b84-4709-9b98-3f8b5d3395f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_CityAreaCode_dd6a1231-0b84-4709-9b98-3f8b5d3395f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a8e06c84-d2ea-4d86-9c89-7671fe7e6f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_LocalPhoneNumber_a8e06c84-d2ea-4d86-9c89-7671fe7e6f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_dc27cedd-3fd2-424e-8e2b-60dde8648c28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_WrittenCommunications_dc27cedd-3fd2-424e-8e2b-60dde8648c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_46fd1ce7-a63a-4e52-96da-a50b51f975d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_SolicitingMaterial_46fd1ce7-a63a-4e52-96da-a50b51f975d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_83ca005d-1bce-4603-835b-a6fde93fe38b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_PreCommencementTenderOffer_83ca005d-1bce-4603-835b-a6fde93fe38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_97db25c0-5025-4190-be36-16eadcd87d93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_97db25c0-5025-4190-be36-16eadcd87d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_25622538-78b6-462e-906b-3407c27f1fc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_Security12bTitle_25622538-78b6-462e-906b-3407c27f1fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_449af8d7-e611-4792-bd7d-1b982bf1fedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_TradingSymbol_449af8d7-e611-4792-bd7d-1b982bf1fedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dacbdea5-2383-44bf-9b0a-6769fbdfcaeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_SecurityExchangeName_dacbdea5-2383-44bf-9b0a-6769fbdfcaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b0a76094-d7c3-43ed-b2ab-bef7e1a2b91c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityEmergingGrowthCompany_b0a76094-d7c3-43ed-b2ab-bef7e1a2b91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e998b688-31c3-48d4-b7ab-2547277c1da1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_AmendmentFlag_e998b688-31c3-48d4-b7ab-2547277c1da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_917c3b44-7865-48fd-bfc4-2873e6ae4b2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b09ea2d7-b983-4066-9dc4-37931a13395d" xlink:to="loc_dei_EntityCentralIndexKey_917c3b44-7865-48fd-bfc4-2873e6ae4b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20230503_g1.jpg
<TEXT>
begin 644 nbix-20230503_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139927166249696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nbix-20230503_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20230503.xsd" xlink:type="simple"/>
    <context id="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN180L2ZyYWc6MTc3ZDM4MTNlYjdlNDZhYmFiMDg3NjkxZDlmNDVlOGEvdGFibGU6MGRlMDFkMDQ3OWU2NGY2NDhkZWUzYTZmZWYxZjk4YjAvdGFibGVyYW5nZTowZGUwMWQwNDc5ZTY0ZjY0OGRlZTNhNmZlZjFmOThiMF8wLTEtMS0xLTE3NDQ3MA_a9a292d4-598e-4ddc-a2da-588172012b05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN180L2ZyYWc6MTc3ZDM4MTNlYjdlNDZhYmFiMDg3NjkxZDlmNDVlOGEvdGFibGU6MGRlMDFkMDQ3OWU2NGY2NDhkZWUzYTZmZWYxZjk4YjAvdGFibGVyYW5nZTowZGUwMWQwNDc5ZTY0ZjY0OGRlZTNhNmZlZjFmOThiMF8xLTEtMS0xLTE3NDQ3MA_188b887c-70b0-4193-89d7-f9790b502907">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAy_4245022a-a924-4e4c-912e-82bca186da13">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8yMjI_8a6da6db-7247-4498-97ea-bbbbb6b2de73">2023-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAz_b3c7dc7a-4207-4a01-9599-a1ffa19a7454">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk3_59708936-7215-455b-affb-849dbd03afd5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzky_0bc5aeb8-b38c-42e1-905d-6e7c6410334b">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk4_4cf2bd07-078c-494d-b9ec-a4aceb9ba188">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk5_37710e17-c1aa-4ba0-8d2e-9fe168453bae">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAw_95fb4e93-13ae-49a1-bbaf-3f87550df4cf">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzkz_1204249c-6d6b-4ab7-83b8-f1256dab13d7">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV81MjQ_ec650a7f-7de1-4545-a09d-3eca7f297abe">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV81Mzg_c8af3bb9-7cf2-4bb9-b447-1b47817bb83f">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzg3_bd2ef453-5fa5-4486-9349-21e8793eb130">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xODAx_fcd8a377-4df4-4898-b6d1-0815678d252a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk0_0bc6c2d8-83bb-40a8-a17a-9cdb5a833a82">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzk1_6ecbdc44-1591-4792-be79-11df10cb2c1e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzg1_ea68de5f-02e7-4f0a-a53b-e8ffb6d60f8f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTAtMS0xLTE3NDQ3MA_4bf3d6dd-e50f-43a6-b6e7-aecfc0e06de7">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTItMS0xLTE3NDQ3MA_0c4c5208-5d17-44ba-8fb6-df64960c56da">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGFibGU6MGFmZTM4NmJmZjYyNDMxM2E0ZGRkNWZlM2FlYjNmYmQvdGFibGVyYW5nZTowYWZlMzg2YmZmNjI0MzEzYTRkZGQ1ZmUzYWViM2ZiZF8xLTQtMS0xLTE3NDQ3MA_f5c363f3-bd2a-46b1-8318-62984a0d234b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYjdhOTBlNDY4MTQ5MmNiNDVmNmY0YTVkYzNhY2Q3L3NlYzo1YWI3YTkwZTQ2ODE0OTJjYjQ1ZjZmNGE1ZGMzYWNkN18xL2ZyYWc6ZDExNzkzZDQ5ZTRmNGIwYjlmNWM2OWYwZTMyYjc3MDUvdGV4dHJlZ2lvbjpkMTE3OTNkNDllNGY0YjBiOWY1YzY5ZjBlMzJiNzcwNV8xNzkx_7146d33f-6471-487b-810a-6a2dad76d578">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML=P.+=<ZGECP]4:;$_9HD-(U"YC^DLX5C.Q2)>()$QF7@BBV&EIC]^[>:YN
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M, HV86Z ZRLI]7%@-JSE[PVC?P%02P,$%     @ ##RC5I^@&_"Q @  X@P
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MB^$_7G\!4$L! A0#%     @ ##RC5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  ,/*-6^VT\2^X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    (  P\HU:7BKL<P    !,"   +
M      "  6L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  P\HU:JQ"(6,P$
M "("   /              "  500  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  ,/*-6)!Z;HJT   #X 0  &@              @ &T$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  ,/*-699!YDAD!  #/
M P  $P              @ &9$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  #C$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20230503.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-20230503.htm">nbix-20230503.htm</File>
    <File>nbix-20230503.xsd</File>
    <File>nbix-20230503_lab.xml</File>
    <File>nbix-20230503_pre.xml</File>
    <File>q1-2023xearningsrelease.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20230503_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20230503.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nbix-20230503.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20230503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20230503_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20230503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20230503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20230503.htm",
      "contextRef": "i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.neurocrine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20230503.htm",
      "contextRef": "i91dd9cfb6c424b35adb656f6917b6a80_D20230503-20230503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000914475-23-000043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-23-000043-xbrl.zip
M4$L#!!0    (  P\HU9O[^-X-!,   ]Y   1    ;F)I>"TR,#(S,#4P,RYH
M=&WM/6ESVDC:W^=7],N\.^M4N4'W@1-O.8"]S 1(,(D'OKA:ZI81%A*1A '_
M^GVZ)3 &[)#,$..Q794*HL_GOEK-V_],AP&Z87'B1^&[@ER4"N@_QV__#^,_
MW[<_H&KDCH<L3%$E9B1E%$W\M(\N*$NND1='0W01Q=?^#<%8C*E$HUGL7_53
MI$B*NM(8ER7-LF7;5K!!+0MKCD8QH:J$->:IMNZX&E64PZNRZ<F.SBP9NY+M
M8DW6=&P[U,$&4RQ9=F3)<(Q#6M:)8Q);8IIAR9JMN(ZF>X:G$9VZ*G&IR9?M
MIP =0!@FY6GBOROTTW14+I4FDTEQHA:C^*JD2))<^K/QX=SMLR'!?IBD)'19
M83XJ\,/K3>, #KLD6O.N#W?BFYC/YT]3G##W7F=X+EY%-R4_A.D8QWLIC4F8
M>%$\)"G0!38IZUBRL"K/YZ'L#IJI$P>+2: !NBO*W8+WUA)],[AE=6G%>?<U
M<)<&2&J)-SLD84O@;.[]&"R*A"4%RXLM\D'^(XO>HTDY(.'5NP(+\>?S A"8
M$7K\=LA2@OAXS+Z._9MWA4H4IL"VN#,;P3 W>WI72-DT+0ERE(Y_^>67MZF?
M!NPX=/PIY@PKZ9+ZMI1]^;:43>U$=';\EOHW*$EG 7M7H'XR"LBL'$8A@PWX
MTS+OR.+LHT\I"\5':&^"[,2^FZT_3=O,>U?P;9E2V_4<P]44S5%U0AU#-SS#
MEDW'()9T69UO9;&G @K)D"_-_/()B"/E(GD:D*L"\BE,2=4O,Z<:W7Q0VC==
MM3&F@]I-[\P>M 9?^MT![;<Z[X-FM:LU.I_TQK#I-ZM?ALUA5^IVOEQW;YO]
MKO))_: V@^YM)'<OZFJW<SWI=3XIK6I-:G5^'W0'G^3>H#=LGM7DWEGCMGO1
MO&[*EO1!Z<VZ%Z[1Z+AJK]J ^6&. 86U>OWN\-1O5*_4YN!ZVJL&0U@S:)W5
M;NC9J>^<?38:9^V@43V];E0_J:V+STKSK*LTJ_WKWL7GVVZG-^Q==*>]P;76
M'9SD8[[ 6GK8ZT23WMGG2>/BTZ19=?5>IROU!EVI!?/U.LU^<]@+>H/38:O3
M]QNGUN1#IY8VSJ4I_*\V8:W&R26QB6(K5,.Z;3&L4>IBHE""=<N239 +Q9'T
MPK%'@H2]+=VCY"X)6PN!\685H&Q,@GI(V?0/-GLE\+<(/-U 8-FR',LR76Q*
M#E@7V5:Q98-!\&S3EAQ=4FS)+!Q+\&?+FF;J:U0NW1?EF'DL9J"!D@T:B*O$
M<B*L!_ !$B:AG(+>>5=(_.$HX&I+?->/.9O<4S;%:4)ABM+].;+U[Q;-]Y!$
MXU@\"7U9SGDO8Y ?X;WY1$PPWOS)I_S9\UF,Q(;81E-5J?]Q'X&K@X_G7]V?
M?03XC>C\"=1ZG%;!KSCFF\(2V#AU/NZN;;%-^D#7><O\>;Y(Z1ZBYEA=H+&T
MI+I+H. S+2_0^2W7XE(N+(_)+</0#W&?<?>GK&NC]&CBT[1?EB7I7P71[_AM
M,B+ 44Y<@M'9YVR2M:GXAC$)_*NP[ (&65S(!L_;W2B(XO*ODO@[\@!"[)&A
M'\S*_^[X0^#3)IN@=C0DX;\/$S"_X'/$OI=U3/Q;5I85V*!XG&0[-F$>;K+G
M$,@*W_;G9KU3JZ+SSDFG=GY_SWNXV_-:Y7.[WJG7SM%)LXIJ?U;^>P(J#55:
MC4;]_+S>:CX(PI#$5T ^)TK3:%@V8+E] >J")'T_O$JC\!!5BY4BN-:Z9N\5
M(,96@)RVV@VT0P,ZCU4RG^\I[>9T;C=[U=JT>7M]VZM^ CO6AG[U27< MO*B
MH;0NNC!78]8=N&JC^AELX!>-_O?WH*<$-\Y@=-T >];JP'S5( #;*74'[WT8
M(W=ONWIO\#YHW/[N-V_=2?.+-6U53V:7@#0P;0K!Q%8TB*DT%]NRPK"E."Z1
M+8,2&92^A?]8-W=/)M?;<0Y(=;O6[*!V[6.KW7F&K/]Q'"=C F%T&J%SYO(X
M",DJBF(DZP?T#8H\E/89;QK'?NK#PK6IVP<W@Z$3-^7-X,-H^P2XO0*WMA%N
M;I;Y[MML%,4I.I@_,P*&F24I8C<\N1"+9D;?E.<@[G2OFVGT,U331^&9U#)_
MI8"RH!BFGZ9E"M_@(:S9Y\,P)3,\ S1A%KXL739K#.J7%@%M95 'FXIF8DVS
M+6R;C&"'_QF.0ID)JJQ!9K_]*AO2D7HH\DU;Z[7MY,4?7J$D=E=<]LLKN3@8
M0>1-@C1KRA[SJ7.6,LW1].C^,CHL<\/BU'=)D"\E5LV:<V=14Z31M%#:8UV\
M\PBXS:[\A.>,TB:TO"SFYX;\]M)179.Z)L' #<#]1)*QK=LV)K+G$=DFIJ9K
MA>-F[7.[56G7FS7TOMXZK]1KS4KM_!#5FY7BJB2@YV<Z#FI3 J:/<P>W&/&"
M*Q!)4#)B+@\S*?)#Y*<) F,)!B1^\R"<BUBL*"WBL=6,7I:SQ$X0N==KHAJ-
M<A%5K*)NRBM3[ $:GTA<ZZ$;Q6"^17+W/ 4K5HG&81K/*A&];^)XWIN']2D;
MQ=$-G^>EV3:^AGJIVZ9DV:H!QDW6L:;K#B:>YV!+LZE#)95X5 ?7B05D0N+U
M#.3/\) VBZ1(7!P(&G/7-0*7-48#\%@3Z@N?5G0 8?67>>+--U(=&Z5O2*8X
M$S>S*&O*OXYX;B7[PB@:_(MU^=R4DGD5[;\@VJ=^P&!V!P!\<6(ZNY0<5R?,
ML;"C6BZ88@966-(I-ICI&IHLJ:KF%(XEK"BFM"&#_,126HF&0S])YD+)28DR
M6CXW>=1>Y3&7QPZ9UO,$NRM4ZTL53NU2<ST%;*6))9,+IZU1[-C,Q40C+G-L
MA\B653A6>:% T65M_^2SWCY'M>$HB&8L%M_<IRQJ1L6-@KI#QU8SBIIBK4SQ
MD&QMJF+\S&AU3T3RA-*8)4G^WP?8@/SRQ%&_5$U3EIAL8E<F$+8Z1,(651BV
M/28;EJ:K#F&%8UDQ+0G5 E0!4H<1:C,2[$\N>K\XJ@(?6W$GFKRT$*E5/9E<
MVKKG:,Q6L:P2!NJ=R-AQB(=5SS)U7:(>Z/_"\3E0O^JSJVB5B0YWF<N]1R81
M#+7BCQ#0^N*$THNB%5_C$N0"\&B[V*"&@S7BF-A2P6WV9$4W*'%DE9J%X\K)
M_DKZ PFHG,0\^S2*@;K^B 2(39D[3OT;GI0"8\V2O]^=EG?E3G,#KZ[Z"*\&
M?ALY_Q@E*0EZ_BC+:KTD*9<;@T^7S#5TB9@>-BG$P9JNZ9A(-L4J<^%;Q3:)
M P;>5F15>G9R#E1%G*S;^=MY^ E2]4)B3^Z)G,2,O$3.O[VZ="WBJ8YC8Q-"
M3G!MX9.C:2:6'<VT (..I8(K<F#IUIOUJLONJ/(A @W_L1^%+S5#=Z5>.A!B
M>!!<8-TC.M8TR\"VJME8D9EEVBH#UT,J'!L0EIB&M*:7GF--[*XV^MNOEB*;
M1PE*6<!&G ]0*!CAD&??@S'UPRM$0&R!Z]94VV.P/@UDE3YSK\49&#(:Q1'X
M6[S(X$13Y+ @FB _.R!S&L5#9.$_D.<''$ _ 6A3%E)&^=&:Q!^.@Y2$+!HG
MP0PE)/43;R9&Y@,B!XB895CR,S=+A<4QS!,C$L[F;5X4P.)\'*]8^3R;FJ"#
MA#%TQD(6@SM8#V'L6!0_$G125(K9?N\.LNPKPG>HFBYB/P6:\ ST.,SS6<EZ
M)=")HL A@. 4R/S"U!<$N=-+SZ4644T3:Q#/8LVR+>P85,:2)>N&:5%%5TCA
M^+=?;5/3CM:T%\K1#*1;QC,:+1TU:X\#AC1%SSE[Y8@9/UEV()NH<MI&0,4B
M=-Q[/;%#MCV/ M\%S(17#= ]H(""5YY="?8E7A0S7(5:/,2'8%\B%B:R2;#M
M4D<GEJH22WF$9^]PC(8YDM<95M8(EI4EGKUW%G+!L9I4S'J^9*;]&#.N9_EK
M(N+H,S>%<<OSN$/XRKSWF%>^-)CK4%?3L*S;$,2:MH(=9MI8EJDG2ZZCN#)[
MA'D!U]A=0O8W-:^L4:P<.&^V8^6L[RLS+_!;3Y(QBU]9^N$02+YDQ+ HTSTL
M*0P<"4\BF.BJ@YGE 1FH(7F6][>RM,JP=N!NQ])YW[UGZ26?*(L&6 SQQ&C3
MF7TASGET /!^GYN?$@=0F'=PHA@P"-@/ C)*6'G^X6@EIRL&_<A1XJ62<!K#
M/[I2,2Z*IE)*U]M4K:@9^H/-0-H?;-,U[8=&/K99Q2@JUL/-^[59@5ESJVE+
M@FH9Y8 Y.)^]*QB+@^8C0GF,7U9&4R1O2E&L<DC&'#\]/2ES/NKP5^JS%S_<
M/G(#DB0+R<GQ\.Q!C(G(N9S/ADX4/ B=^CRA:^;'L 7]V%SC@T:<]'WXYDYM
MW@/\&RR<JT">2@<$H 2" XKFH'PW>K(2V<\U'P(WNXQ),\LTDQ5'B-"S=''F
MUP&<#N%[K3G\?=@;=&?-:F/:4&I2[ZQ]W;SH!0WE-.@.8)?#3VO7 71Y^^V5
MTAW"G@9UJ7%;N^UVVM>],]CG\#/L[XO?4'I^3UP'<+)Z'8#F>"HU*,5,ESRL
MJ<3 C@'N$F&NYTI,,BCC%6IP?8"AS]/(O3Y$_\^-IXQ&)$8W)!@_> S[$?7U
MRM[?8N]<9V8J\Y6WM^#M^BIO2Z[FZHID89W*_$TYAV +Z(&I9VBV(;G\" :H
M[_?U/[?F8/65@[];0<^#H.R5M=4PE1O,9_R^R\]F\D^K3.[IKFJHGHH=JA"L
M&8Z,+56VL*'8ED8DJHBC^$V24/(5G0610P((V0((VE"#Q-<L?93WA9=2$G'6
M_L:H]9#RJ)PA9X9<42R#C5V#^\7$6S@KE2P_0;!#".GYWJ_051Q-TCX/[D>\
MND421)D'2XC7Y[(B@:1O> G][MUS%1WP5VW-(U$HF'?VQ8MW(_[B'7\A*,L0
M* Y6MGRA?3$ISQ;<C5N:MKCON8/: SC>^<&D^<)G8MU*MNQKAFPEZ3N]-&7-
MH*KJ84,S9:Q9IH,M62+8X%=^4=.@NFD]F"';DOO4)],*WB-RSD\";%0:_EKE
MNP\J0>A+4 EA)%)>XX2)7L"U>7V=7^/GBS18=L$2YS6Q5C#CBXN;(3GKAP :
MM,3LQD]@'"@:$KJ\TD-<E[\:RCOS"_THB6F25=;I0_DV]8 L\FW+&J2(%A1;
MH=!6IQ>7;VD:11E4Y9@%A)_L7+NWZ<X=$M26[H80!WRB<;H^Y%M7/7WO?5/F
MXO1G/[Y+(%PQ[,2,7&/B@;(LDV!"9@F_/> [+J6:]^/: @.Q8^*FY60\!$Z9
M/:N<I5)45/7O3]CM<-KMTHMY$F6%=64]2RD_FEJ2N&->>-3%_ZM=-SA/:]+V
M &O]O;=72%N=DZRG;(B4HJ04=_(&V-HN-JMMA-#/67XS$MHL&0>I.-C> E6>
MUWI (:/3A:ZN1& [>,,W/;#\).S.";H9E:T0K5X#<PASC^/(C:$S>N]'B>N+
M:Q0/43UTBP!G"%;(Y<XOX.#..L4Y5KA5RTZ,Q4F*OH[%Q1(HLX$03;C]?#$Y
M6ZV(.KSS. B0N(XQ-U8C\>H F!1&P)#ZO)0IO&UP!,/<N F#*8Z\Y3L2%3CN
MNJ<I 7--N:->F_9]QT^1;1=E;AF%=UP9QS'OFU^K!'/-#\;M.;7JH7 "8LJO
M\\T0L.$D'7I?%)' '*A#@24_7-PAS!'Y#40L'X-<QN$A2OK@#@LOQV$0!P'6
M*>*G*14 W \8%9_E(\$'X). K6="5!8^B;5E='/(Z4>&&><<\ 'Y,LN=\]7>
M+"Y4F(#3A)*Q,^#1JR X0X%/'#\ IS];F:0HR39S"'#$.43^,D!W-S#  WA_
MB\M$.>JXDY:?AWSP8%@>]BW#<(BB]8KO(:\&L)&XE85-!=?SDY<LY?@#\L+:
M^64M[OU-)&,7W,5\'UNQ+;\O\2G-AEV4Y)=L-NZ,@WCKC6NKS&KD\I5\#Q6?
MC5]I% W5>B;595LJ:O)VF]U8FMNJ.!DP;PWCNRE-?ILO!4ES]ON.DNMW.+O/
M 0%5EH"S,Q(W\&PHOZY$#NHC@<.#"?^CW804W[G>CS.M^%&*)R+:FC(71./.
MR'ZP[")=L0$%GK<S%&3[H\S-[XDJ"U^$]X(]D8VQ(\LD_>C)-XBRN]R_RB)!
M.V4D#@'S2>[N%_LIX/6CB #:>01 A2<&H0I:7%9)5C-#/R:S/SO8_X?(GRQI
M^R%^3P%\)8+=H(\$?/@Z+]6"</%7VJLD)8A?%?7]];$5!_V?EG^5I9TE8)^1
M+_R:8]W;'.M3W'V^7=AX7C]KGG0^MQ_Y_8B=UW*W#+"7KVG/*F1?QWZ<1[K;
M)GTVE-;H.)@AEXQY.4SDK;(+S_DR#@@^D @:HNPF6X?U2>#QO F?2+@<>8<^
MB]DXA#%B.C).^U$,P-%M:^0""4OJ6G]>@;BF%U7EQR+QQZ;5E:)F*D\0,^_@
M.-26UC]+8/^U(\I[%P0_?AWVMPXE_S#,0Y_2@/W#"+EO0.U"\!Z+>G<*'__I
M!UI>JUIMB 6?DU!NAK64E #0%"S9!%6*Z,1A<<C2_FSGU-T3QOU[C]7N'7E?
M2?L\A'.SQ:ST?>8ME?Q;XD*[[#;:@^I]'S._[2X6]9Z/V6UXX#:N#7[S'9F#
M/4D"E+)?>!4_"WO\/U!+ P04    "  ,/*-6NNAO;FH"  !T!P  $0   &YB
M:7@M,C R,S U,#,N>'-DS55;;YLP%'[/K_!XGKDG2U"32FM5:5*V25VK]FTR
M]B&Q"C:S3</^_; #2DDO:Z0]C!?,.=]W[L><G;=5B1Y!:2[%THO\T$,@J&1<
M;);>[<T5GGOGJ\GD[ /&]Y^OU^A2TJ8"8="% F* H1TW6W3'0#^@0LD*W4GU
MP!\)QBM'NI#U;\4W6X/B,$Z.M2H+T_DB6BQB/&/S.4[SE&'"DA"G4"2+:4Y3
M%L<?-]FG(LJG,(\P#1<4IU$ZQ8N<Y7@&\3R*\BB<Y3-GM-69IENH".H2$SIK
M]=+;&E-G0;#;[?Q=XDNU">(PC(+[K^L?#NKUV)*+AQ&ZS54YX)/ JG.B88"+
MG+<CN(!&2:JX )_**K )A],P\1 Q1O&\,7 E574)!6E*L_0:\:LA)2\XL*[H
M)=BRC@!/U(:H#9AOI )=$PKO<KN:(&3KP:M:*H/$B^2^(%T+%D%K,_30OGYK
M28EQ0_%J01P>VR..8IQ$?JN9%[S+[=@0%]H00>$4W]T7'GC_(H9#=T^+8>"=
M'H,SIH'Z&_D8,."V<_'+[O5K<'O ]C#V2820QO&MI)?5-1>%W LZD0T\&Z*_
MAF)8F&=;\,*(N%=&%%6R_,L\!;62-2C#03_=(&=@JZ!8>G:/\#"U/TN2^UTD
M ^29@W$+K#KH*%"N#YD,7/.[[KBZ:T )^]K\SXG7"DY-O*/H[M)PC3XQ?\N_
MZ?2(LZ5W(;L_@(>L[/;ZRUN7BW.[AP_V!HL,"BZXF[G0/1'"A]\%1HYU%AQC
MCZPT&MAWL7+GX_1Z<@]Y@TA)29OR=-XAK%=IO7 H7[]>P7B_]M]/=M )]HN]
MFOP!4$L#!!0    (  P\HU98;/FC/D8  -)'   4    ;F)I>"TR,#(S,#4P
M,U]G,2YJ<&><NP=04VT4-A@$I0D(2"]1Z4VD"=(B(B B(+V33VD"TD4"A$1!
M>I,NH* "(E(BTFOH541Z;Z'WA!(":1O_V7]W9V=W9W=/<C-O)C>YIS_/>9.0
MI\G+@&N/=?5U 5145(#_*#< >06@J@-Q=P4 # T!D@  @ Y ;7(-0$594?U[
M,&$%T/Q; _ZMV?[W]3\ASP&T 9>HJ/[=_U>AODS]3Z[0T%!?IKU"2_OOH*-G
MI*>C8Z"CI65@8F!@O$H16GIF%J:KS/_6_S[DW]O_O8MROTI'2W?U_[.0VP"L
M= !#JD)JJEN 2ZQ4U*Q4Y"X D*+K9:K_(?]39:I+U#27KU!48F"DG%!SC:(^
M-?4EBK*7:2BF48517@?0L%YFNRFG=87=Y!GM+;_K\F]3OM )/:ALYS =00LK
M//</IV?@Y.+FX141%1.7D%14NJNL<D]5^Z&.KMXC_<=FYA:65M8VMD[.+JYN
M+]P] EX%O@Z"!(=$O(N,BHZ)C4M-2\_(S/J0G?.UH+#H6_'WDA^_JJIK:NOJ
M&QH[.KNZ>WK[^@=&Q\8G)J>F9V974*MKZQN;6]L[F*/CDU/L&>[\XI]=5 !J
MJO\I_Y=VL5+LND2) 0WM/[NH+@7].X&5YO)-N2ML6B:TS_S8;\F_I;O^(.5+
M93N]D((IFN.Y_P@#I[#BB@CFGVG_P[+_=X:%__^R['\S['^W:Q9PE9J*$CQJ
M5@ (0"1\_3Q^JA;&95C?W%P?-?EG5#0G>,,WI2..WM55_3* 37^9"JP!6R #
M:A- 5)J79APA,*_%6YAT.T73[:CP6U_RM@H"CDIO_]5;#.QKN]5X9]HC8^>'
M^6394=7>)E.ZRT3 $\\:28]]DGZ0UXS(1+4VWID,:-<C*./EANY&%[;EB6)2
M$4.NJ?MU8T?R5P_DM;:@-><QN]77C#>1/:"Y8]19#V-_SEF/;5Z:F^C]7R/V
MV^A;%ZX*&\H$^J'@\O7YV<2U*2X% S^_ "$#Q=&&8-'7]RAZ9PJGZN]X?.IN
MW2$*74YY]O.O;8!!*;S8"0>*5W<<#IA_DE_SZL720O&5T;JSG*JTPS#97[J.
M-2@-)[,&]XK Q.<;S_V=,R]L@,<R.7_1B'TN#'"E>N"")1GJ5+2O+JQ:O0'J
MN?O\72BKQ91^KFE+W.0L3X5W!9_STTZ>5'V[$?-+^MA++:'M(/03X\1\MK))
MU%2[F?OKPX%61"!'/"L98#]]GI\SDF N@5BLSOJ$-$N+6O2)+X76<HB)-(6G
M>4[T^F3/0Z^0 >&+A$>X@$ F1%+U/JC7]O%[A/JC6M5TS[&;Z<%&87$2H$6.
M"Q'\'=A,/@L9X#G,K'$6$9B1=S"C[>@>)+6V-.V6O/C0Z/6%:J;V3"+,93<?
MK0M/RJSM>?0JF6FQ5F&]O>RS#R','%:S"KN-X\ D8Z4P8?FQ"$4@!T3,9'1]
MP:NL+;=\I"E957Z$0X-!KI,ZG GZ1X@Z D&@%Y$5NX"GX#>T>SY:I!81JQX4
M;IT&)%2TB$ZMB.(=O&%8$_!M>+L2&;#\=1)4&QVQ-AI85#M*NOG"-QI9G;P>
M;1(?B3<''%>G4HN)<"=]+@&93/V>+% U\\V9 /[-=G2/^NU;V?-,9(C>ZZ)X
MIN*[E&P/3&E4DQ]G27'>5(V4 %!W=$69*ZLN3?J.G:YJ4]-_DLEFMAG'AP0.
MGWR<&$N/,9[3&_[^NVV3@'5<TB<)<P=VN+\JHRQ.'-SVZ3&6#Z(I2[B7&9K-
M*9X2B'_95,GP&4K4OV%5:764M586-S!09/U?0B!B?AAW\XQPG17I 7Z[V083
M;SUN#EOF>Q4S*.5J"#;B?E2A0##ZJ'?S=+J7Z.)IFB79J.DFBO(IG\)R?/VZ
M.+F[ $_!6G4AXF!\..45&Z5A3L]&JVC%%\Z/"EO&O4T7:8+43 PJJ87? PX\
M$]%6^PAT-$HOKNP5B(7P!*U94[9CY%1=635Y(P>U'IYYD]4Z4\T\3XW:D9H,
MN(SFH>2&'R2"U,D+)F6(P&PH)26:SH(3/^MPI"5$%I$!HP9Q/UZ9?U[KO(N2
MK'_2D\?,:FB0916ZLP<[AEH3"]0OHV]Y<A/<5X%,.$O#IVJVMTN^ZWEX/_!:
M- OFJSVP7_VV8A]#N<8[ B/HV HF0(DC=HD,B$.\A2^OW\SG@ +) (27'1GP
MH!H1"7<%3I,!O<A:8*R2H=@**<6]%/RBMC_X==IB]PNAV ]?WSO?4/ZMRC":
M)R@?K9B]OD%P2.AT96M;V2JI\?0)>I4W.$[< **?^KR-)GEL=@X3!.?( (S%
MUB(O+GF%#."!\ +9MU7_Y)9 7J,6*KZ.EU=P&MC<LC]X_XAYM,"]_X^*$@Z6
MCWXH.WL?_CNK@ Q8T7(C [JG=H+V1M#1CCAZ,H"F?PP*1,4_*@LDTG98U4[5
M8OY4%1K_<FT+%+&+XH\PLTU4*5R5RHLR^+1AG5.5I,"\W2/G=;>PXF3,K R,
M$Q=KF[H_B E8V3:59\'N(\D #L<6FNT !GT^J=Y;499F[]N.Z!#K1]UZV"?J
M+*<&<]-6)[LKP',.1>3%23P9<)_#NDR^R%/C-P04Y^G&_*/\LJ"1G>W%(I%X
M%1X'XH,"T7K&-4V8Z-AJT-79I<?_U669-1LXY]UGY#!=<UYF?SMM:=4)G\U:
M0?8 *;W#"6?5Z\B!X?Q^TS/"O=C#Q-YPO80JWZ-23<NE_XP#XT;@UU5 ZZT@
MB0EF\&WAC.-\PK573MB=+%)WZ"&1S\O*F)[G::!/1?%MM02IO\,KZ;HY?FEQ
MK75GJ;!/QA,(0=@DDI'$!?FQJHT1ZV*AVPH9^JR;-X WCZ)',7])_Z5P2;Z0
M->_S)*6!9[6;D0%*=FT@G%H=&8 J/;(C,0HK4+*3"]-+#'7/O]!F\D52P?]#
MQ"U5(\/SNQSIT?G8R42!L1FEWKG]<HS\9>DFYQ2[-X-_Y(8"QP;=53T*USV+
MIL^;@V)F"A5XIZ\*<IC[IJ?6*7CIS&+!L?C89=E9GY7A;ADM+W7E523=;E8J
MOTQ+9CG-F!Q6QZL7S3%O==R+:<*^P$SM#:,,#(#\$%<RH#,K2]*E*O5!,C_^
M47^<]4QZ1M\?/B$AE3[$"!AW:VE_ <42=Q82W;'$LV.VRS7KD(6-BOZ^H(G/
M]AK)$*Y+&;YM%B)?.>@E3:^FXQ8[&"R!MS5MU&#FP]RR_MWNDIW!XF32)'.V
M.*28X_/M; 3X^;278$;\#&5!/YAQP03%JX-6_J[ZBYSN^?;?.#47"X !I@9!
M: L?G(0,1<FK,"JT^E]$DI*!G\;ZN<F-O_MS-Q^7+/_!B6C[_E"^YE]S'KRR
MQ CIQ$;BHH5M [-BU-U1Y8^J1]-M9'U$3X,"4KF(WV[JU5BR2 8^V_?0M"8#
MP'[\#JA ]:KK1WN-6;5EU:$SFI.V_6>/)V?/&L$U(5R$Z]'+X)A3X>H:W*<5
M/\5HC_/CFD9VTLE;JU.$\TA-$XAU^_V2^]GKNLD@QE:I^&!+ZR*PA8LPZX$4
M>K@'B38^3 0RJ]\3+2V#JF!H0J 2&P8B]7%['9^=,Q\Y3%/-K\8A\.*DZ45%
M8@K4COG+2M@#_>IL8::PK\8W[ZJ&!PV<Z,M]?%1_X[2O3\.TW_T/_W3P B$?
ME9S3CFM/ZGCNI*?9WNB795[$F06S 6<'53E:31,7O]8?O@'Q*QK/JJT(QJ\"
M6?J&BSVO'1XM"7I5O\E(Y:%UT[UL/"9$028*V%S6H_2LM%U>4((22Q2()5!"
ML?(;:=5Q4B;7JSV+?[9M-7V66:!WJ&F=YEGLD6\];\T.GKM4"9ERD<7J%^60
M[A*O6'[[Q>/Y.-6&VHKRHTDBUWQ8#48!6X +0'MOEQ-,5GV8MNH,)F=1YY?;
M+GKHX:.5!#Z\'_0F!ONU-L2JRX?!WN%>Q\.S0<9[)Y<,&T"/"0XX)W10-Y(/
MJN7GO@)F\=04'><ZRQ(=Y?SPS7@Q4[MC<V+:M;95BO0;?$V3;J;7;Y7ERJZM
M0,)O5F_O&RPOK4_,;G'>[_TIS [6$@1V$MA*#J%(F>'.'<A"WH LCYZL8[N&
MP[?1TYS'$H3DA>]K-B8V-C;6SM?\Z<K( "Y<KSX.OC)8[F0_7G;R2?+WE;R#
M@V=7[X2WZVYX7[%^.^PO=62'9:(X+!(2@?T/XY647 %VV%EBJ2BTKO 2#9!R
MO_$Q&+MV]"6DVFG]V4? M-+9)N%Z(U; &$N+F>AN3AGV\7-WES85\K:YOM"F
M33W/&I%SY,?S9.OY,UT??<4TQUK\R(6K/LJ17;FOTN8;\]W2Z'=%DOZA2EPB
M/VI6I6S4Q I&%*J M4$=_]J(4#L8IQQ!09CB3KP35*P^P\DXAL0HW0N >[:!
ML!X$6[15Q"E+C*#,Z(G&K;G]D(I*_\S,]S[FQT4!D0Z_[_-H]%]JB>X"HHUD
M$QTY1XJ1C6B!M4SL@*.65Y!7P.V1*=;"R-PM*J4#XVA?7P\E*9L6A#/,. +3
M&8M)7[>[G"GY/NE KD2X<6=B=,S!>%J NBL$'G?2=_BJ":_Q^(]Q@T;9KJ+Q
MB8LP;^[3\1NC+\4:&W/40CVM9VV*4FH+7Q1(=V$!EP+ L?"JS7T65/),?B_G
MQ6;DX;>ZZ>6%:87\7SNL$;_]BXWTJ"H;C&_$$0,QM%V,P#@RX%=2"<I!.6@Z
M<(EQ.)3.I_GMODUMOM]'H*]GW^]?-BMB'*$]1E.@)\M #E^"X3N$B,',5(&@
M&^."DIL;E_-^H&MY8&#+@1SH)3A2WFL.P]=>W@1PLHS^2 :TE99AEKJ&6:"R
M(P7CZOKE[B$"":,Q0O6M]=9"P73"XJXWG"/%!'N05U]U\Y5#@"&@#:F3)A(C
MOP)>>@N$E;.#;VMT!ZVJP#+X=7@E#4MJ\V9MES:@< ;<R ?7!E&W'(O.#OD.
M7;8X(\LL9:7#H+![(< '. -L)BYT=?B:W;:J;")4[H='D%USKIV#KH1KU@OI
MU]]??@08"T2^/L7IK0Q? T.TNSA5:[,"1)**OOW)LJQC]?W;]T[^YP4K[@0Q
MC:#P"6QF);$$QC@-"0=*,ID"3QQL1XP)(0OB?#]5]UY&FQ$GJ;\K#7]R-K[,
M89KK'S]R#L*)-:V XT=0.1.^*K-^18Y2.1+*[GKEB$G9P FU\NPIZ -<YPKX
MW> +J#%*AJ\31:BOQ8?-VIVO^S5YHQ02.U6V4RP(U)BY=CB'TKTR@A*JG-:Q
MJ3;^3R8?W_0F9.R&]TW]&\YO\T-PFR1&?P5W]!2I<0=TP=3BAT3K5"8G+TJ3
M 950^/:35V;])8,R%X<*K8VO%CMZ($6)!;T&[R:X\<KB%:&M/B$Y>7/>^UMA
M,ZCA6;N5PS<$;;_"74<E])^,'[9>Q_O>-=Q?<V0&N+U-_>4+@5\HA8Q[:1P)
M.C&!\I$!$2_@N!^$,4K-9HJ#:J<2ZTE2QD3AJ)\D1E(G&< &>B%[!=ZAM>+
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MLM7G_1:Y3MP',B*]YBE:]LD6S_[R#A'3D&L[K=QDP/1"(1FP_5+IPH(,H 7
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M2ML8ODIJA[,3;"H@!?I3E('^FOO3Z?LY]G[J*8V/[3./!:[<"64+ .O!VP=
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M498-LOLD'&ON-3)(9</MKR()T?Q(?9\"EPQD@"LP%HA^VG)EJ3>?A^""\F'
M63F8!'Z% #NS$I_Q<Y;_-@X0YRM\;<K,HG)C/: R1/8:A8;>K):EG>[_#I7
M16+X5C;CO,9KRD=WTQQM'ZU^'6+_^"NMO7U[^@2!\-I?K:Y+$D]Q2E*BBRE@
M^.P+$ S/OP]4@+4!:Y!QK5([)$F<)T;;V% 9%=TY\]!JM)/5P,MU_J/,./3R
M00-C.W,"X*I%,&+&R;:% OSAI;"1UP%@QR$WSV>%W%YK]:^C+CVSWWOPNB)T
M^>K4U/0&Q>_IH'7II>HL8L0)G'BMFJH3:H%C_08;AZ.MDCDA>ETY=7'EKPQ
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M4,H@7_-U=F%OLH@]_S5[:>@U9B'+MH6W37A5V.(QI!2;B'N+KD,YM$8O#W-
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M C-U))DDJ0.,#!9VP2%!/(?LH?\ *6;]I+_L'Z/_ .B%K[%AA2WA6.-5CCC
M554850.@ KD/"GP"\)>"/BQXD\<:7I*VOBCQ='#%JUZ)Y&-VL2A8P49BBX
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M<5]"T %%%% !1110 4444 %%%% !1110 4444 %%%% '_]E02P,$%     @
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MT7\3SE/#OV8;3HM[K1MQVMJ[5YP?_AW@[\KR+.5A&C&,0'W"!C-*09HP'XA
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MVTE[)[Z,[>Z>W9<]$ E)F%"$FA<[ZE^_50!)4=;5BB61-/JA(TN\ '7YJ@I
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MX<KGRTNF+QE$C#+VI] K:?ON;;M:K9S$6HQ_FJT3_\GD8](,X4Y'NE!((#\
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M+CQQ64".'.'[[S$O3(QR>]A)8]WAIG $6-><BUVUV7N%HF#6C(Z./9X)PA$
M,^JY,&X_E1TFT\K-$V)S)PR8K<%9:^2SP;EBM#H:G+4HO/E8,<S5QPAU2*)#
MDDRLQ.FPY-"L* #<'=4[1D-;/BT*;SY6]WA6H%! K$.3K+*H %H)H4G#U "M
M10%#D]K>$I9U:*)#DZF OG")I]P>X7H>?[)7=6A:9*SG;5J[:0OYS@4MSIC%
M1CUPU:;D*&Q%)I68;5%_6)+_)^S/D#]01]8OQ<.6(^I]8U&-26:%'@_X? )W
M-.BE"8ZO(5TU3[FJ9@ESLE8?L-ALHGOU+;5\Y4:^JNWVFC6#W<J7A.ACB5L?
MYZOHIAMBS-=L7]8B(ZJ36YG>0GLP;(C?YVY9VCPC_?^A-Y7[ 2OW/$:_E6D?
MK.$'ZCS2B?]FQYT\#MDF8F7U^9DN!3LNC+^R3CG9S\M7]SA84'C_5QY51']2
M2G$U0VLH[DJYR@B('SHQ2'+7!HO_H=PY2&>0%37BF[ONB[!B"+.TJANRWG;"
ME-E2];+>/NZ[C-,E"<DC\YAJJ!%%.-*G&G@PO%KSO\ $CL;48S9Y\(T%Q?]G
M',],LS:'C+QE%E@@XH;2U1=]X-[CM'2_!S$ V (;N>+1\838X/I&%>YGF01W
MSL1+JRJV5[.!J*G.0<\$$IR%%K7GBMKG>:A(]FEQAT""@OPPW2# 1CRMU@QL
M_(1G44K8%6/,+/14G$EI"B&R4\(\?DS?I+:"Y9,6;$C@^\SZT_>9]=GW:?G8
MDWRXZ;W\53+2J#SE6<-\MHS,O&V]G-3FWEFKY$Y."N&-G/%^'UP,V2F.NXM\
M$LE6Y%+"8S'&3DUHS-CW,7-]N'6M@-@>Q_8VO<GV5@+;E629O9U6I9HA]K8:
M2)VN]6?(D3$7;ADB  O['45%0,C1Q4U<E2GF9(3B4QA?+!-/^^O W=@4$ZZ'
M^V5>-1MP"YPA+W"9YP_Y6%WWNYA H.J1>^D3L1#"[Z3M5?3;^SS(1AXE :CL
M8><C.^%_S'/@L1_*AE3(/NHJ=JJN8-AUZ %=/>Q7--?Y2?-JU[R*<V(39HT]
M#L2%84! P; CF' '0G)'C$;,DSXYL"G@<BEJIM\4AAXV&SMB$O>7PF\29LN
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MZERR7"VYF0#"WQ(H*,5=3W]S\:P5N0L ")3^GU*7VM0@?Z!7J=@NE[NIU."
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MMI+PIW6\YR3<; !Y;E1!B$TRMUXMC2Y<&X82I OS[(1,GGIG$4FHUJ DG*;
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M5Q8(BJ^$6Y9-OSBN!3(_('*/&^O?"YC;:\J+J>AJ;3NBZZ$2'C1R[ ,YZ$C
MJ/Y2'EP*/:CU9\BQDP9_6O.QJ/BA2]#E.:NN(!B2O0'GY<H=@7-RUF_?BG,Z
M!-B%QW&7]"GWR -U0D9$/SK7OK#T/(D5[$4'W#0:&XQXP3E+W#4HUXP%1YUP
M]0 ?\.:C^>3$8J' [ZAJ5)=MVVF#LB5-S8[1V3]1<P=XV1MP7JXLFB6YD&=
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MM=)V4RM-%T7;=L*Z*%J!X#,/BT;2)[.$+T-,CSTP-US:85J?W<G),EI[3:T
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M8.1\_']02P$"% ,4    "  ,/*-6;^_C>#03   />0  $0
M@ $     ;F)I>"TR,#(S,#4P,RYH=&U02P$"% ,4    "  ,/*-6NNAO;FH"
M  !T!P  $0              @ %C$P  ;F)I>"TR,#(S,#4P,RYX<V102P$"
M% ,4    "  ,/*-66&SYHSY&  #21P  %               @ '\%0  ;F)I
M>"TR,#(S,#4P,U]G,2YJ<&=02P$"% ,4    "  ,/*-6A"'?%$(*   870
M%0              @ %L7   ;F)I>"TR,#(S,#4P,U]L86(N>&UL4$L! A0#
M%     @ ##RC5@0=I3BE!@  X#   !4              ( !X68  &YB:7@M
M,C R,S U,#-?<')E+GAM;%!+ 0(4 Q0    (  P\HU:;^=4BM2L  *&A @ ;
M              "  ;EM  !Q,2TR,#(S>&5A<FYI;F=S<F5L96%S92YH=&U0
52P4&      8 !@"/ 0  IYD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
